Myeloperoxidase – Marker und Mediator vaskulär inflammatorischer Erkrankungen

Abstract

Myeloperoxidase (MPO), a heme protein abundantly expressed by neutrophils, monocytes and macrophages, has been suggested to critically accelerate the course of vascular inflammatory disease: Myeloperoxidase not only has been localized to atherosclerotic plaques, it also binds to and transcytopses endothelial cells to accumulate in the subendothelial space. Here, MPO remains catalytically active and is capable of oxidizing lipoproteins, matrix proteins and nitric oxide, thereby adversely affecting endothelial function.

Multiple clinical trials suggest that circulating MPO levels identify patients with stable and unstable coronary artery disease as well as those with heart failure and peripheral vascular disease, who are at risk for adverse cardiovascular events. Given the powerful proinflammatory properties of this enzyme, MPO suggests to be both marker and mediator of cardiovascular pathology and emerges as both marker and potential target of treatment.

Literatur

• 1 Naruko T, Ueda M, Haze K. et al . Neutrophil infiltration of culprit lesions in acute coronary syndromes.  Circulation. 2002;  106 2894-2900
• 2 van Leeuwen L M, Gijbels M J, Duijvestijn A. et al . Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR–/– mice.  Arterioscler Thromb Vasc Biol. 2008;  28 84-89
• 3 Buffon A, Biasucci L M, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina.  N Engl J Med. 2002;  347 5-12
• 4 Rudolph V, Steven D, Gehling U M. et al . Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease.  Free Radic Biol Med. 2007;  42 460-465
• 5 Baldus S, Heeschen C, Meinertz T. et al . Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.  Circulation. 2003;  108 1440-1445
• 6 Brennan M L, Penn M S, Van Lente F. et al . Prognostic value of myeloperoxidase in patients with chest pain.  N Engl J Med. 2003;  349 1595-1604
• 7 Baldus S, Eiserich J P, Mani A. et al . Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration.  J Clin Invest. 2001;  108 1759-1770
• 8 Baldus S, Rudolph V, Roiss M. et al . Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase.  Circulation. 2006;  113 1871-1878
• 9 Meuwese M C, Stroes E S, Hazen S L. et al . Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.  J Am Coll Cardiol. 2007;  50 159-165
• 10 Zhang R, Brennan M L, Fu X. et al . Association between myeloperoxidase levels and risk of coronary artery disease.  JAMA. 2001;  286 2136-2142
• 11 Stefanescu A, Braun S, Ndrepepa G. et al . Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease.  Am Heart J. 2008;  155 356-360
• 12 Morrow D A, Sabatine M S, Brennan M L. et al . Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.  Eur Heart J. 2008;  29 1096-1110
• 13 Khan S Q, Kelly D, Quinn P, Davies J E, Ng L L. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction.  Heart. 2007;  93 826-831
• 14 Cavusoglu E, Ruwende C, Eng C. et al . Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome.  Am J Cardiol. 2007;  99 1364-1368
• 15 Mocatta T J, Pilbrow A P, Cameron V A, Senthilmohan R, Frampton C M, Richards A M, Winterbourn C C. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.  J Am Coll Cardiol. 2007;  49 1993-2000
• 16 Tang W H, Brennan M L, Philip K, Tong W, Mann S, van LF , Hazen S L. Plasma myeloperoxidase levels in patients with chronic heart failure.  Am J Cardiol. 2006;  98 796-799
• 17 Rudolph V, Rudolph T K, Hennings J C. et al . Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function.  Free Radic Biol Med. 2007;  43 1189-1196
• 18 Tang W H, Tong W, Troughton R W. et al . Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.  J Am Coll Cardiol. 2007;  49 2364-2370
• 19 Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Scopacasa F, Chiariello M. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease.  Eur Heart J. 2008;  29 224-230
• 20 Exner M, Minar E, Mlekusch W. et al . Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol.  J Am Coll Cardiol. 2006;  47 2212-2218